---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-023643"
form_type: "8-K"
ticker: "CHRN"
cik: "0001549084"
company_name: "EKSO BIONICS HOLDINGS, INC."
filed_at: "2025-07-28T23:59:59+00:00"
generated_at: "2026-05-18T00:15:25.149689+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ekso Bionics Q2 revenue falls 58% YoY to $2.1M; net loss $2.7M

## Summary
- Revenue $2.1M vs $5.0M in Q2 2024, down 58% due to lower Enterprise Health device sales.
- Gross margin 40% vs 53% prior year; gross profit $0.8M vs $2.6M.
- Net loss $2.7M ($1.24/share) vs $2.4M ($1.99/share) in Q2 2024.
- Personal Health device sales grew >50% YoY in H1 2025; cash $5.2M at June 30.
- Named Bionic P&O as first Ekso Indego Personal distributor; joined NVIDIA Connect program.

## SEC filing metadata
- accession: 0001437749-25-023643
- form_type: 8-K
- ticker: CHRN
- cik: 0001549084
- company_name: EKSO BIONICS HOLDINGS, INC.
- filed_at: 2025-07-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549084/000143774925023643/0001437749-25-023643-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549084/000143774925023643/ekso20250520_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-023643
- JSON: https://secwatch.observer/filing/0001437749-25-023643.json
- Plain text: https://secwatch.observer/filing/0001437749-25-023643.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.